Go Pro
NYSEAMERICAN:IGC

IGC Pharma Q1 2026 Earnings Report

IGC Pharma logo
$0.28 -0.02 (-5.98%)
As of 04:10 PM Eastern

IGC Pharma EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

IGC Pharma Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IGC Pharma Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Friday, May 15, 2026
Conference Call Time
8:00AM ET

Earnings Documents

IGC Pharma Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
IGC Pharma Executives Convert Debt Into Equity Shares
See More IGC Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email.

About IGC Pharma

IGC Pharma (NYSEAMERICAN:IGC), a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

View IGC Pharma Profile